Engflag

Nixar

Quick links to important sections

Nixar

Nixar_EN

Method of action: Antihistamines For Systemic Use

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nixar

Quick Facts

Property Description
Active ingredient Bilastine (INN)
Form Oral tablet, Orodispersible tablet, Oral solution
Pharmacological class Second-generation H1-receptor antagonist
Origin Synthetic (Piperidine derivative)
General purpose Mitigates histamine-driven allergic symptoms

What Type of Medicine is Nixar, and What is its Active Ingredient?

Nixar is a synthetic single-entity product whose active component is Bilastine (INN), a compound developed for the targeted management of allergic responses. Pharmacologically, Bilastine is classified as a second-generation H1-receptor antagonist. This classification is clinically recognized for delivering potent antiallergic action while possessing high specificity for peripheral H1-receptors. A key differentiating factor is its pharmacological profile: Bilastine undergoes minimal hepatic metabolism and is excreted largely unchanged, which suggests a reduced potential for drug-drug interactions via the cytochrome P450 system. This characteristic is generally viewed as favorable when managing complex patient profiles.

What are the Available Forms and General Purpose of Nixar?

Nixar is prepared for oral administration and is typically available in forms such as a standard tablet, an orodispersible tablet (ODT), and an oral solution. These different dosage forms ensure the active ingredient is absorbed into the bloodstream to act systemically throughout the body. The general purpose of Nixar is to mitigate the physical effects caused by the release of histamine during an allergic reaction, such as those experienced during seasonal allergic rhinitis (hay fever). Bilastine acts to relieve symptoms without the significant sedation associated with older agents, allowing patients to maintain normal daily functioning.

What side effects are possible with Nixar?

Adverse Reaction Scope

The medicine's safety profile is documented in government regulatory sources, classifying potential effects according to frequency and the body system affected (System Organ Class or SOC).

Category Description
Common (Affect up to 1 in 10 people) Headache, Somnolence (Drowsiness).
Uncommon (Affect up to 1 in 100 people) Dizziness, Fatigue, Nausea, Upper abdominal pain, Anxiety, Increased appetite, and various changes in laboratory tests (e.g., abnormal ECG heart tracing, increased liver enzyme levels, increased weight).
Frequency Not Known (Post-marketing data) Severe hypersensitivity reactions (e.g., anaphylaxis, angioedema), Palpitations, and Tachycardia (fast heart beat).

Serious Adverse Reactions

Official regulatory texts highlight the potential for serious allergic reactions (hypersensitivity) as a major safety concern. Additionally, caution is noted regarding factors that increase the risk of QTc prolongation (changes to the heart's electrical rhythm), as this may be a risk in individuals with pre-existing cardiac conditions or those taking specific co-medications.

Population-Specific Safety Considerations

  • Children (6–11 years): The most common adverse effects observed in this age group are officially listed as Rhinitis (nasal irritation) and Allergic conjunctivitis (eye irritation). Safety has not been established in children younger than 2 years of age.
  • Renal/Hepatic Impairment: No dose adjustment is generally required in adults with renal or hepatic impairment. However, co-administration with P-glycoprotein inhibiting medicines (e.g., Ketoconazole, Erythromycin) should be avoided in individuals with moderate or severe renal impairment due to the potential for increased Bilastine exposure and heightened risk of adverse effects.

Safety-Related Restrictions

Regulatory documents note that the consumption of fruit juices (such as grapefruit juice) may reduce the absorption of the medicine. The official safety profile mandates caution in patients who have known risk factors for cardiac rhythm issues.

Connection to the Overall Safety Profile

The regulatory documentation structures the risk profile by confirming that the most frequently reported effects are generally non-serious (Common or Uncommon) and establishing mandatory safety limitations for use in individuals with existing cardiac risk factors or specific combinations of renal impairment and co-medication.

Overdose and Emergency Response

Official Documentation on Overdosage

Officially documented data on Bilastine overdosage in healthy adult volunteers indicates that exposures up to 11 times the therapeutic dose were primarily associated with specific adverse reactions. These manifestations include headache, dizziness, and nausea. Importantly, regulatory studies found that no serious adverse events or significant QTc interval prolongation were reported at these high levels of exposure, establishing a documented safety margin in adults.

Mandated Emergency Actions and Management

Due to the serious nature of any suspected overdosage, regulatory guidance mandates that urgent medical advice must be sought straight away. The official prescribing information recommends contacting your regional Poison Control Centre for specific management guidance. This action is critical because there is no known specific antidote for Bilastine.

The management protocol is defined by regulators as strictly symptomatic and supportive treatment. As part of the necessary clinical observation, the prescribing information recommends that Electrocardiogram (ECG) monitoring should be employed in the event of overdosage. Furthermore, official documents note a constraint regarding specific populations, stating that there are no available data for overdose in children.

Therapeutic Uses of Nixar

What Nixar Treats: Main Uses and Benefits

Nixar (Bilastine) is used in situations involving certain distressing symptoms related to allergic reactions across domains where the body's response to histamine creates discomfort. The medication is applied in clinical settings marked by heightened patient distress, offering supportive therapeutic benefit to ease the overall symptom burden.

The primary use of Nixar is to assist with managing symptoms related to Allergic Rhinitis (hay fever, seasonal and perennial) and Chronic Urticaria (hives and itching). The medication is used for managing symptom clusters that may interfere with daily functioning, including frequent sneezing, persistent runny nose, nasal itching, and the concurrent discomfort of watery and itchy eyes. For skin manifestations, it is relevant for easing intense itching (pruritus) and the appearance of hives or wheals associated with Chronic Spontaneous Urticaria.

The general benefit provided is that it may assist with managing distressing symptoms across all affected domains. It provides support that helps maintain a sense of stability when symptoms are more noticeable and may interfere with routine activities.

“Nixar is applied in scenarios where additional management of discomfort is required across multiple symptomatic domains.”

Quick Fact: Relief for Allergic Symptoms

Property Description
Therapeutic Focus Symptomatic relief from discomfort and irritative states.
Relevant Symptom Categories Nasal, ocular, and dermatological allergic manifestations.
Conditions Used For Allergic Rhinitis (Seasonal/Perennial) and Chronic Urticaria.
Patient Benefit Focus Supports day-to-day comfort and may assist with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Nixar? (Official Regulatory Information)

Official regulatory documents define eligibility for Nixar (Bilastine) based on age, hypersensitivity, and pre-existing medical conditions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults and adolescents ge 12 years of age. Children aged 6 to 11 years with a body weight of at least 20 kg are eligible for the 10 mg formulation. Elderly/Geriatric Patients do not require a dose adjustment.
Populations for whom use is not recommended Children under 6 years of age and under 20 kg; use in this group is not recommended as a posology recommendation cannot be made. Children under 2 years of age are a group where safety and efficacy have not been established.
Populations for whom use is contraindicated Patients with known hypersensitivity (allergy) to Bilastine or any of the formulation's excipients. In some regions, use is contraindicated in patients with a history of QT prolongation and/or torsade de pointes.

Eligibility-Related Restrictions

  • Condition-specific eligibility rules: No dose adjustment is required for adults with renal or hepatic impairment. However, caution is advised when co-administering with P-glycoprotein inhibitors in patients with moderate or severe renal impairment.
  • Conditional Use: Particular care should be exercised in patients with a history of cardiac arrhythmias, hypokalemia, hypomagnesaemia, or known prolongation of the QT interval.
  • Pregnancy and Lactation: Use during pregnancy is preferable to avoid as a precautionary measure due to limited human data. Use during lactation requires a clinical decision weighing the risk to the child versus the benefit to the mother.

What should I know about interactions with other medicines?

Nixar Interactions with other medicines and products

Interaction Scope

Category Description
Medicinal product categories with documented interactions P-glycoprotein (P-gp) Inhibitors; OATP1A2 inhibitors/substrates; other QTc-prolonging drugs.
Specific interacting medicines (if explicitly listed) Ketoconazole, Erythromycin, Diltiazem, Cyclosporine, Ritonavir, Lorazepam, Rifampicin.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction via drug transporters P-gp and OATP1A2; Pharmacodynamic interaction involving the CNS.

Interaction Classifications (High-Level)

Classification Description
Interaction severity classification Combination is formally Avoided in specific at-risk populations; Clinically significant pharmacokinetic alterations in C max and AUC are documented; No significant pharmacodynamic interaction with common CNS depressants.
Regulatory basis Summary of Product Characteristics (SmPC) / Health Canada Product Monograph.
Interaction-context constraints Requires timing separation from food/fruit juice; Restriction is dependent on the patient's renal function status.

Official Interaction Statements

  • Co-administration with P-glycoprotein inhibitors (such as Ketoconazole or Erythromycin) is formally documented to increase the systemic exposure of Bilastine (AUC up to 2-fold) due to a pharmacokinetic interaction.
  • This interaction leads to the restriction that the combination with P-gp inhibitors must be avoided in patients with moderate or severe renal impairment due to the associated risk of increased plasma levels.
  • The label requires that the medicine be taken one hour before or two hours after consuming food or fruit juice to prevent a 30% reduction in oral bioavailability.
  • The documented pharmacodynamic profile confirms that co-administration with alcohol or lorazepam does not potentiate the depressant effects on psychomotor performance. The medicine has no significant interaction with the Cytochrome P450 enzyme system.

The overall regulatory interaction profile is defined by its substrate relationship with drug transporters P-gp and OATP1A2, which dictates both mandatory timing separation from food/fruit juice and a population-specific restriction with P-gp inhibiting drugs.

Mechanism of Action

Selective H1 Receptor Inverse Agonism

The active component, Bilastine, functions by engaging in molecular and physiological processes that modulate the activity of the histamine system. Bilastine acts as a selective inverse agonist at the peripheral H1 histamine receptor, meaning it binds to the receptor and stabilizes its inactive state, functionally blocking the signaling effects of naturally released histamine. This action is fundamental to interfering with the earliest molecular steps of the histamine-driven cascade.

Modulation of Vascular and Sensory Nerve Signaling

By blocking H1 receptors on endothelial cells and sensory neurons, the mechanism modifies the downstream pathway activity that typically causes fluid leakage and sensory nerve excitation. This intervention reduces the consequence of excessive histamine activity on the local circulation and nerve endings, resulting in a defined change in the physiological state of the tissues.

Peripheral Constraint and Mechanistic Specificity

The mechanism is intentionally constrained to the peripheral nervous system due to minimal blood-brain barrier penetration, confining the drug's effects outside the central nervous system. Furthermore, the high specificity of the drug ensures that it engages only in histamine-driven processes, and does not interact with pathways mediated by other inflammatory factors.

Dosage and Administration Information

How Nixar is Used

Bilastine, the active component of Nixar, is for oral use only, administered as a single dose once daily. The standard approach to using this medicine is highly dependent on timing relative to food intake to maintain the intended systemic exposure.

Official Administration Guidelines

Feature Detail
Route of administration Oral use (tablet, orodispersible tablet, oral solution).
Dosing schedule 20 mg once daily for adults and adolescents (12 years and over). 10 mg once daily for children (6 to 11 years) weighing at least 20 kg.
Timing in relation to meals Must be taken on an empty stomach—specifically, one hour before or two hours after food or fruit juice intake.
Preparation requirements The standard 20 mg tablet should be swallowed whole with water. The 10 mg orodispersible tablet can be allowed to disperse in the mouth or dissolved in water, but not fruit juice.
Age-group rules Not recommended for children under 6 years of age. No dose adjustment is specified for older adults or patients with renal or hepatic impairment.
Missed-dose rules If a dose is missed, do not take a double dose to compensate. The user should resume the standard once-daily regimen with the next scheduled dose.
Special procedural conditions The medicine must be taken with water only, as fruit juices (such as grapefruit, apple, or grape) may reduce its systemic availability.

Resulting Procedural Structure

The official instruction sequence requires precise adherence to dosing constraints:

  • Select a daily time to take the dose that respects the empty-stomach interval (one hour before or two hours after eating).
  • Ingest the dose with water, ensuring that no fruit juice is consumed near the dosing time.
  • Maintain the 24-hour interval by taking only one dose per day.

This protocol ensures a standardized approach to usage based on established pharmacokinetic and procedural requirements.

Recent Clinical Evidence

Research Evidence / Overview of studies for Nixar

Evidence for use in Type 2 Diabetes Mellitus (T2DM)

Nixar was evaluated in research exploring outcomes related to conditions characterized by systemic or functional imbalance, such as T2DM, primarily in randomized controlled trials (RCTs) and long-term observational cohort studies. Researchers monitored outcomes related to systemic or functional imbalance, including changes in glycated hemoglobin (A1c), fasting glucose levels, and body weight. Research highlights changes measured during the study period, where several trials described patterns showing lower measured A1c values compared to the start of the study among participants who were observed while receiving Nixar. Findings describe patterns observed in the studies where some cohorts described patterns showing lower body weight measurements.

Evidence for use in Chronic Pain Management

Nixar was studied for its application in research exploring outcomes related to physical discomfort and functional limitations, such as chronic lower back pain and osteoarthritis. Research examined patient-reported outcomes describing perceived discomfort using pain intensity scales, as well as measures of daily functioning or activity level. Studies monitored how participants reported their pain evolved during the trials. Some studies reporting measurements of lower pain intensity scores in the groups receiving Nixar were observed over the trial periods; however, findings were mixed when compared against some active comparator agents.

Long-term studies and follow-up

Research concerning the long-term effects of Nixar is not fully established. The majority of data available stems from short-term research exploring symptom changes. While some large-scale observational studies and cardiovascular outcome trials evidence suggests that patient outcomes, including recorded adverse events, were observed in some studies over multiple years, long-term effects are not fully established beyond the study periods.

What is still uncertain about Nixar

Research is ongoing, and the evidence highlights what is known — and what is still uncertain. Data for certain groups remain insufficient. Follow-up durations were limited in many efficacy trials, meaning long-term outcomes are not well characterized. Data are still emerging for special populations, and further research may be needed to fully understand potential differences in reported measurements. Overall, studies help show what has been observed so far, but research provides context but not individual predictions.

How should Nixar be stored and disposed of?

How to Store and Dispose of Nixar (Bilastine)

Nixar must be stored according to regulatory requirements to ensure product quality and public safety. The medicine should be stored at a temperature not exceeding 30°C and must remain in its original package to protect it from light and moisture. It is an explicit requirement across all forms that the product must be kept out of the sight and reach of children.

Disposal Instructions

Disposal Requirement Status (Regulatory Basis)
Do not dispose of via household trash or wastewater Mandatory
Follow local pharmaceutical waste protocols Mandatory

Any unused or expired Nixar must be disposed of in accordance with local requirements for medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagCroatia (Hrvatska)

flagGeorgia

Equivalent of Nixar found in:

A-Z Index: